At a time when the number of biotechnology-based patent applications is soaring, it is essential that the law allows a significant 'experimental-use' exemption. The United States urgently needs to modify its legislation in this area.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bruzzone, L. Amer. Intell. Property Law Assoc. Q. J. 21, 52–69 (1993).
Stone, R. Science 268, 656–658 (1995).
Eisenberg, R. Risk: Health, Safety and Environment 5, 163–175 (1994).
Parker, D. Houston 1. Int. Law 16, 615–663 (1994).
Roche Products v, Bolar Pharmaceutical Co. 733 F. 2d 858 (Federal Circuit, 1984).
Scripps Clinic and Research Foundation v. Genentech Inc. 666 F. suppl. 1379 (Northern District of California, 1987).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ducor, P. Are patents and research arch compatible?. Nature 387, 13–14 (1997). https://doi.org/10.1038/387013a0
Issue Date:
DOI: https://doi.org/10.1038/387013a0
This article is cited by
-
Patents and royalties
Nature (1997)